THU-192-All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive noncirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china

Autor: Wei, Lai, Xu, xiaoyuan, Guan, yujuan, Zheng, sujun, Sheng, Ji-Fang, Yang, xingxiang, Ma, yuanji, Huang, Yan, Kang, Yi, Wen, Xiaofeng, Li, Jun, Tan, Youwen, He, Qing, Xie, Qing, Wang, Maorong, An, Ping, Gong, Guozhong, Liu, Huimin, Ning, Qin, Hua, Rui, Ning, Bo, Xie, Wen, Zhang, Jiming, Huang, Wenxiang, Yang, Yongfeng, Lin, Minghua, Zhao, Yingren, Yu, Yanhong, Jia, Ji-Dong, Yang, Dongliang, Chen, Liang, Ye, Yinong, Nan, Yuemin, Gong, Zuojong, Zhang, Quan, Hu, Peng, Wang, Fu-Sheng, Li, Yongguo, Li, Dongliang, Jia, Zhansheng, Hou, Jinlin, Chen, Chengwei, Wu, Jinzi
Zdroj: In Journal of Hepatology April 2019 70(1) Supplement:e247-e247
Databáze: ScienceDirect